Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 6/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 6/20 | 0.37 |
| ▸ | KCNE1 | P15382 | 4/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | JUN | P05412 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20397416 | 0.85 | KCNQ3 (0.37) | KCNQ3KCNQ2KCNE1KCNQ1NAPRT | |
| Acetic Acid SCHEMBL28092089 | 0.84 | ALDH1A1 (0.44) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL30456319 | 0.83 | ALDH1A1 (0.46) | RAB9AMEN1KMT2APOLBNPC1 | |
| SCHEMBL27083575 | 0.81 | RAB9A (0.38) | KCNQ3KCNQ2KCNE1KCNQ1NAPRT | |
| SCHEMBL16443989 | 0.81 | NAPRT (0.35) | KCNQ3KCNQ2KCNE1KCNQ1NAPRT | |
| SCHEMBL16165291 | 0.81 | KCNQ3 (0.40) | KCNQ3KCNQ2KCNE1KCNQ1NAPRT | |
| SCHEMBL1971452 | 0.78 | GPR65 (0.43) | KCNQ3KCNQ2KCNE1KCNQ1RAB9A | |
| SCHEMBL1427509 | 0.78 | NAPRT (0.35) | KCNQ3KCNQ2KCNE1KCNQ1NAPRT | |
| SCHEMBL23924532 | 0.76 | POLB (0.40) | MEN1KMT2APOLB | |
| SCHEMBL21262226 | 0.76 | ATR (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| EP-3749672-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2020-12-16 | — | — | EP | disclosed |
| EP-3728267-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| WO-2019153080-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | KCNQ3 3600/4885KCNQ2 3655/4885KCNE1 3092/4885 |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | KCNQ3 4051/4885KCNQ2 3988/4885KCNE1 3467/4885 |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | KCNQ3 4138/4885KCNQ2 4010/4885KCNE1 3602/4885 |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | BCL6, BCL6B, BCL3 | KCNQ3 4138/4885KCNQ2 4010/4885KCNE1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.